Hot topics in pharmacogenetics of age-related macular degeneration

Stephen Schwartz, Milam A. Brantley, Jaclyn Kovach, Andrzej Grzybowski

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.

Original languageEnglish (US)
Pages (from-to)547-550
Number of pages4
JournalCurrent Pharmaceutical Design
Volume23
Issue number4
DOIs
StatePublished - Feb 1 2017

Fingerprint

Pharmacogenetics
Macular Degeneration
Vascular Endothelial Growth Factor A
Complement Factor H
Proxy
Research
Therapeutics

Keywords

  • Age-related eye disease study (AREDS)
  • Age-related macular degeneration (AMD)
  • Age-related maculopathy susceptibility 2 (ARMS2)
  • Complement factor H (CFH)
  • Pharmacogenetics
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Hot topics in pharmacogenetics of age-related macular degeneration. / Schwartz, Stephen; Brantley, Milam A.; Kovach, Jaclyn; Grzybowski, Andrzej.

In: Current Pharmaceutical Design, Vol. 23, No. 4, 01.02.2017, p. 547-550.

Research output: Contribution to journalArticle

Schwartz, Stephen ; Brantley, Milam A. ; Kovach, Jaclyn ; Grzybowski, Andrzej. / Hot topics in pharmacogenetics of age-related macular degeneration. In: Current Pharmaceutical Design. 2017 ; Vol. 23, No. 4. pp. 547-550.
@article{9e6fa9dc02b44adca1737d8d5a3a77cf,
title = "Hot topics in pharmacogenetics of age-related macular degeneration",
abstract = "Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.",
keywords = "Age-related eye disease study (AREDS), Age-related macular degeneration (AMD), Age-related maculopathy susceptibility 2 (ARMS2), Complement factor H (CFH), Pharmacogenetics, Vascular endothelial growth factor (VEGF)",
author = "Stephen Schwartz and Brantley, {Milam A.} and Jaclyn Kovach and Andrzej Grzybowski",
year = "2017",
month = "2",
day = "1",
doi = "10.2174/1381612822666161208114847",
language = "English (US)",
volume = "23",
pages = "547--550",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Hot topics in pharmacogenetics of age-related macular degeneration

AU - Schwartz, Stephen

AU - Brantley, Milam A.

AU - Kovach, Jaclyn

AU - Grzybowski, Andrzej

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.

AB - Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.

KW - Age-related eye disease study (AREDS)

KW - Age-related macular degeneration (AMD)

KW - Age-related maculopathy susceptibility 2 (ARMS2)

KW - Complement factor H (CFH)

KW - Pharmacogenetics

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=85018490770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018490770&partnerID=8YFLogxK

U2 - 10.2174/1381612822666161208114847

DO - 10.2174/1381612822666161208114847

M3 - Article

VL - 23

SP - 547

EP - 550

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 4

ER -